Profile data is unavailable for this security.
About the company
Bio-Rad Laboratories, Inc. is engaged in developing, manufacturing, and marketing a range of products for the life science research and clinical diagnostics markets. The Company offers a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components. It operates through two segments: Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables used for biological research, biopharmaceutical production processes, food testing regimes, and science education. Its Clinical Diagnostics segment designs, manufactures, markets and supports test systems, informatics systems, test kits and specialized quality controls that serve clinical laboratories in the global diagnostics market. These products are sold to hospital laboratories, diagnostic reference laboratories, transfusion laboratories, and physician office laboratories.
- Revenue in USD (TTM)2.58bn
- Net income in USD759.90m
- Incorporated1975
- Employees7.45k
- LocationBio Rad Laboratories Inc1000 ALFRED NOBEL DRHERCULES 94547-1811United StatesUSA
- Phone+1 (510) 724-7000
- Fax+1 (510) 741-5817
- Websitehttps://www.bio-rad.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TransMedics Group Inc | 566.35m | 90.47m | 4.44bn | 728.00 | 54.54 | 12.48 | 38.22 | 7.83 | 2.38 | 2.41 | 14.48 | 10.40 | 0.6541 | 4.65 | 6.63 | 777,958.80 | 10.45 | -5.73 | 11.37 | -6.28 | 60.28 | 62.37 | 15.97 | -11.86 | 7.13 | 31.19 | 0.5903 | -- | 82.74 | 79.64 | 241.70 | -- | 279.42 | -- |
| Teleflex Inc | 3.19bn | -327.85m | 4.59bn | 14.10k | -- | 1.20 | -- | 1.44 | -7.35 | -7.36 | 70.55 | 86.48 | 0.4154 | 2.05 | 6.00 | 226,240.30 | -4.27 | 4.58 | -4.69 | 5.01 | 53.67 | 54.77 | -10.28 | 11.38 | 1.53 | 6.78 | 0.4114 | 19.74 | 2.45 | 3.26 | -80.38 | -31.40 | 4.25 | 0.00 |
| Lantheus Holdings Inc | 1.53bn | 167.68m | 4.60bn | 808.00 | 29.14 | 4.11 | 19.81 | 3.02 | 2.38 | 2.38 | 21.90 | 16.88 | 0.7055 | 8.67 | 4.48 | 1,888,531.00 | 7.75 | 9.87 | 10.50 | 11.33 | 62.23 | 60.44 | 10.99 | 12.86 | 2.49 | -- | 0.337 | 0.00 | 18.32 | 34.59 | -4.35 | 58.06 | 29.27 | -- |
| iRhythm Holdings, Inc | 702.57m | -51.46m | 4.65bn | 2.00k | -- | 38.10 | -- | 6.61 | -1.62 | -1.62 | 22.11 | 3.78 | 0.7377 | 12.04 | 9.15 | 351,286.50 | -5.40 | -20.12 | -6.21 | -24.37 | 70.35 | 68.61 | -7.32 | -23.90 | 4.50 | -- | 0.8418 | -- | 20.13 | 22.50 | 8.20 | -- | 19.06 | -- |
| Envista Holdings Corp | 2.72bn | 47.00m | 4.75bn | 12.00k | 105.36 | 1.53 | 29.13 | 1.75 | 0.275 | 0.275 | 16.10 | 18.96 | 0.4931 | 4.62 | 6.86 | 226,625.00 | 0.8523 | -2.14 | 1.01 | -2.58 | 55.02 | 56.70 | 1.73 | -5.21 | 2.04 | 6.70 | 0.318 | -- | 8.32 | 7.11 | 104.20 | 2.03 | -1.03 | -- |
| Stevanato Group SpA | 1.39bn | 166.61m | 4.84bn | 5.52k | 26.19 | 2.56 | 18.22 | 3.49 | 0.6104 | 0.6104 | 5.08 | 6.24 | 0.5058 | 2.95 | 2.65 | 251,208.30 | 6.08 | 8.02 | 7.63 | 10.94 | 29.27 | 31.01 | 12.01 | 13.24 | 1.30 | 30.00 | 0.2386 | 6.82 | 1.72 | 15.53 | -19.13 | 24.61 | 33.52 | -- |
| Merit Medical Systems Inc | 1.48bn | 118.43m | 4.84bn | 7.40k | 41.80 | 3.17 | 19.79 | 3.28 | 1.95 | 1.95 | 24.37 | 25.80 | 0.5898 | 2.39 | 7.38 | 199,611.90 | 4.73 | 3.49 | 5.17 | 3.93 | 48.47 | 45.37 | 8.02 | 5.65 | 2.86 | 14.41 | 0.324 | 0.00 | 7.89 | 6.40 | 27.48 | 85.69 | -14.13 | -- |
| Bruker Corp | 3.44bn | -22.50m | 5.55bn | 11.40k | -- | 2.24 | 27.86 | 1.61 | -0.1487 | -0.1487 | 22.61 | 16.28 | 0.5705 | 1.67 | 5.71 | -- | -0.1212 | 5.07 | -0.155 | 6.76 | 46.70 | 49.41 | -0.2124 | 7.56 | 0.8739 | 7.79 | 0.4268 | 13.13 | 2.08 | 11.57 | -119.89 | -- | 4.34 | 4.56 |
| Caris Life Sciences Inc | -100.00bn | -100.00bn | 5.82bn | -- | -- | 12.16 | -- | -- | -- | -- | -- | 1.70 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 9.36 | -- | 0.4404 | -- | 34.67 | -- | 18.22 | -- | -- | -- |
| Avantor Inc | 6.55bn | -530.20m | 6.27bn | 13.50k | -- | 1.13 | -- | 0.9577 | -0.7775 | -0.7775 | 9.62 | 8.16 | 0.5481 | 5.70 | 6.21 | 485,348.20 | -4.44 | 2.78 | -5.17 | 3.18 | 32.65 | 33.77 | -8.09 | 5.00 | 1.18 | 3.62 | 0.4149 | 0.00 | -3.41 | 0.4913 | -174.52 | -- | 15.90 | -- |
| Glaukos Corp | 469.82m | -87.61m | 6.29bn | 995.00 | -- | 8.16 | -- | 13.38 | -1.55 | -1.55 | 8.28 | 13.41 | 0.4879 | 1.76 | 6.06 | 472,180.90 | -9.10 | -11.24 | -9.92 | -12.04 | 76.87 | 73.54 | -18.65 | -36.68 | 4.47 | -- | 0.0817 | -- | 21.85 | 10.10 | -8.70 | -- | 5.93 | -- |
| Bio Rad Laboratories Inc | 2.58bn | 759.90m | 6.93bn | 7.45k | 9.19 | 0.929 | 7.49 | 2.68 | 27.91 | 27.91 | 94.69 | 276.16 | 0.2591 | 1.65 | 5.66 | 346,738.30 | 7.62 | -1.69 | 8.02 | -1.77 | 52.01 | 54.52 | 29.42 | -8.08 | 4.19 | -- | 0.139 | -- | 0.6507 | 0.2935 | 141.20 | -27.58 | 7.74 | -- |
| Masimo Corp | 1.72bn | -203.80m | 6.99bn | 3.60k | -- | 8.53 | -- | 4.08 | -3.83 | -10.61 | 31.70 | 15.25 | 0.6993 | 1.70 | 5.09 | 476,416.70 | -8.31 | 3.29 | -10.46 | 3.99 | 54.96 | 53.94 | -11.88 | 4.56 | 1.92 | 5.88 | 0.4084 | 0.00 | 2.26 | 17.43 | -474.11 | -- | -6.75 | -- |
| Repligen Corp | 707.89m | 1.74m | 7.68bn | 1.78k | 5,298.64 | 3.69 | 92.49 | 10.85 | 0.0258 | 0.0258 | 12.55 | 37.01 | 0.246 | 2.00 | 5.09 | 398,138.30 | 0.0604 | 3.28 | 0.063 | 3.70 | 51.59 | 54.24 | 0.2455 | 12.37 | 7.14 | -- | 0.2052 | 0.00 | 0.3285 | 18.61 | -171.68 | -- | 5.25 | -- |
| Henry Schein Inc | 12.94bn | 391.00m | 9.20bn | 25.00k | 24.70 | 2.76 | 13.04 | 0.7115 | 3.17 | 3.17 | 104.73 | 28.35 | 1.19 | 4.86 | 7.60 | 517,520.00 | 3.70 | 5.43 | 6.36 | 9.19 | 31.19 | 30.23 | 3.10 | 3.98 | 0.7885 | 6.59 | 0.3872 | 0.00 | 2.71 | 4.88 | -6.25 | -11.06 | 19.66 | -- |
Data as of Feb 17 2026. Currency figures normalised to Bio Rad Laboratories Inc's reporting currency: US Dollar USD
47.46%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| First Eagle Investment Management LLCas of 31 Dec 2025 | 2.57m | 11.73% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 1.64m | 7.47% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 1.46m | 6.66% |
| Dimensional Fund Advisors LPas of 31 Dec 2025 | 1.05m | 4.77% |
| Veritas Asset Management LLPas of 30 Sep 2025 | 844.04k | 3.85% |
| Ariel Investments LLCas of 31 Dec 2025 | 764.67k | 3.49% |
| EARNEST Partners LLCas of 31 Dec 2025 | 603.59k | 2.76% |
| SSgA Funds Management, Inc.as of 31 Dec 2025 | 559.60k | 2.56% |
| Capital Research & Management Co. (Global Investors)as of 31 Dec 2025 | 494.47k | 2.26% |
| Managed Account Advisors LLCas of 30 Sep 2025 | 419.55k | 1.92% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
